SLC5A2 and nephrocalcinosis: A number of in vivo studies reported no improvement of renal impairment by SGLT2 inhibitors caused by, e.g., 5/6 nephrectomy in rats (Zhang et al., 2016; Rajasekeran et al., 2018), polycystic kidney disease in rats (Kapoor et al., 2015), oxalate-induced nephrocalcinosis in mice (Ma et al., 2017) and adenine-induced fibrosis in rats (Yamazaki et al., 2020).